Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2014

View Archived Issues

Sanofi reports progress across key programs in fourth quarter 2013

Revive Therapeutics reports interim data from phase IIa study of REV-001

Canadian researchers patent new immunoglobulin constructs

New vaccine company Abivax created

Pierre Fabre obtains worldwide rights to immune checkpoint modulator from Aurigene

Development of a dual serotonin receptor antagonist for the treatment of patients with dementia

FDA grants full approval to Synribo for injection

X-Chem licenses epigenetic program to Bayer Pharma

Aerpio Therapeutics begins phase II study of AKB-9778 in diabetic macular edema

Merck & Co. presents new ROMK blockers

Sphaera Pharma designs new signal transduction inhibitors for cancer

Bristol-Myers Squibb prepares novel P2Y1 receptor antagonists for thrombosis

Agenus aims to develop cancer immunotherapy program with acquisition of 4-Antibody

Bionomics prepares new nicotinic acetylcholine receptor modulators

Scientists at Bristol-Myers Squibb patent new AAK1 inhibitors for pain and other disorders

Preliminary phase II results presented for pazopanib/paclitaxel combination in urothelial carcinoma

Decreased GATA1 mRNA expression associated with poor clinical prognosis in ccRCC

Lilly describes nonsteroidal glucocorticoid antagonist that minimizes treatment-related weight gain

Otsuka Pharmaceutical recaps highlights of third quarter of fiscal 2013

Isis Pharmaceuticals provides update on trials of ISIS-SMNRx in spinal muscular atrophy

Ampio reports preliminary findings from biochemical analysis from SPRING study

Alexion, Prothelia and University of Nevada enter agreements for laminin-111

SwissMedic approves Actelion's Opsumit for pulmonary arterial hypertension

AVEO and Astellas to end worldwide tivozanib collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...